Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing both insulin and dasiglucagon. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Revenue of Zealand Pharma A/S (ZEAL.CO)
Revenue in 2023 (TTM): $48.48 M
According to Zealand Pharma A/S's latest financial reports the company's current revenue (TTM) is $48.48 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Zealand Pharma A/S
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $48.48 M | $45.77 M | $-92,146,840 | $-100,248,119 | $-99,523,197 |
| 2022 | $14.71 M | $10.36 M | $-125,139,560 | $-137,466,629 | $-136,557,153 |
| 2021 | $41.38 M | $24.57 M | $-103,191,506 | $-145,230,479 | $-143,987,250 |
| 2020 | $49.97 M | $37.16 M | $-82,525,006 | $-118,744,238 | $-119,744,930 |
| 2019 | $5.85 M | $5.79 M | $-79,159,337 | $-81,554,012 | $-80,827,676 |
| 2018 | $5.37 M | $-20,118,637 | $-62,508,333 | $88.4 M | $82.21 M |
| 2017 | $19.77 M | $17.7 M | $-35,410,447 | $-39,282,544 | $-38,504,730 |
| 2016 | $33.2 M | $28.75 M | $-16,011,500 | $-22,543,859 | $-21,766,046 |
| 2015 | $26.54 M | $23.39 M | $-10,622,385 | $-16,946,714 | $-16,115,868 |
| 2014 | $21.75 M | $19.8 M | $-9,127,427 | $-10,251,580 | $-9,190,925 |
| 2013 | $929.7 K | $806.38 K | $-25,139,634 | $-25,975,572 | $-25,987,027 |
| 2012 | $31.62 M | $29.36 M | $5.9 M | $5.14 M | $5.14 M |
| 2011 | $20.12 M | $20.11 M | $2.48 M | $1.89 M | $963.5 K |
| 2010 | $12.35 M | $12.35 M | $-14,325,908 | $-14,797,404 | $-14,797,404 |
| 2009 | $3.58 M | $3.58 M | $-10,261,621 | $-10,706,954 | $-11,317,750 |
| 2008 | $7.96 M | $7.96 M | $-4,270,761 | $-4,770,400 | $-4,770,400 |
| 2007 | $8.47 M | $8.47 M | $-8,842,606 | $-7,778,133 | $-7,778,133 |